Methylnitronitrosoguanidine(wetted with ca. 50% Water) |
Catalog No.GC36598 |
Methylnitronitrosoguanidine(wetted with ca. 50% Water) (MNNG) is an alkylating agent with toxic and mutagenic effects.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 70-25-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cell experiment [1]: | |
Cell lines |
|
Preparation Method |
OC3 cells at passage 24 (OC3-P24) were treated with the carcinogen Methylnitronitrosoguanidine (MNNG, final concentration 3 µg/mL in medium) and protected from light. After 24 h, the media containing MNNG was removed and cells were rinsed 3 times with phosphate buffered saline (PBS). The process was repeated 15 times and cells were then cultured in regular medium and passaged when necessary. The induced cell line was designated as OC3W3-15, and it corresponds to regular cultured passage 38 of OC3 cells (OC3-P38) which served as control. Cell growth and morphology of both cell lines were regularly monitored with an inverted microscope. The ultrastructural changes during transformation were observed under the H-600 transmission electronic microscope (TEM). |
Reaction Conditions |
3 µg/mL, 24 hours for 15 times |
Applications |
After treatment with the carcinogen Methylnitronitrosoguanidine 15 times, the OC3W3-15 took on a long- or short-fusiform shape in a multilayer, overlapping and in a confused arrangement. The cells showed karyokinesis or even abnormal karyokinesis. |
Animal experiment [2]: | |
Animal models |
Male Wistar albino rats |
Preparation Method |
Control rats were assisted for group I for 20 weeks. Group II was stimulated oral gave administration of MNNG (200 mg/kg bw) at 0 and 14th days. 1 ml of NaCl for each rats was given trice a day for 6 weeks for saturation and kept till the experimental period. Group III were stimulated with MNNG + Corilagin (30 mg/kg bw) and treated for 20 weeks with effective dosage. Corilagin (30 mg/kg bw) alone was taken as group IV. The experiment was carried out for 20 weeks and all the animals were sacrificed by cardiac puncture. |
Dosage form |
Oral, 200 mg/kg, 2 weeks. |
Applications |
In group II, the rat body weights were significantly decreased compared with normal group whereas, tumor weight was increased and also 100% gastric cancer incidence rats were also recorded. The rat body weight was increased and tumor weights significantly decreased in corilagin administered group compared to group II. |
References: [1]: Ding L, Ding Y N, Lin Y, et al. Proteins related to early changes in carcinogenesis of hepatic oval cells after treatment with methylnitronitrosoguanidine[J]. Experimental and Toxicologic Pathology, 2014, 66(2-3): 139-146. |
Methylnitronitrosoguanidine (MNNG) is an orally active alkylating agent, shows toxic and mutagenic effects. Methylnitronitrosoguanidine often used as carcinogen and mutagen in vivo and in vitro [1,2]. The MNNG mechanism of action is owing to its electrophilic compound degradations, where ammonium ion is the mutagen and leads to the electrophilic impact on DNA base pairs specifically on its nucleophilic sites [3].
After Methylnitronitrosoguanidine (3 µg/mL) treatment, the ultrastructure of the OC3W3-15 cells possessed larger nuclei with enlarged and prominent nucleoli, usually more than 2 in number. The amount of heterochromatin decreased while euchromatin increased. The cytoplasm was filled with abundant rough endoplasmic reticulum, free ribosomes, Golgi apparatus, and well-developed mitochondria, yet the nuclear-to-cytoplasmic ratio remained high [2]. Methylnitronitrosoguanidine (3 µg/mL) treatment increased proliferative rate of hepatic oval cells, and more cells were in prophase for rapid proliferation than in the control group [2]. 2×104 mol/L Methylnitronitrosoguanidine could increase the proliferation, promote the invasion and migration, suppress the apoptosis of GES-1 cells. The expression levels of NF-κB p65 mRNA and protein were upregulated in GES-1 cells after treatment with MNNG [4].
Methylnitronitrosoguanidine (200 mg/kg, 2 weeks) treatment significantly decreased the Male Wistar albino rats body weights, increased tumor weight and gastric cancer was induced in 100% of the rats [1]. Methylnitronitrosoguanidine (200 mg/kg, 2 weeks) reduced protein levels of Bax, caspase-3, and -9 [1].
References:
[1]. Zhang L, Jia B, Velu P, et al. Corilagin induces apoptosis and inhibits HMBG1/PI3K/AKT signaling pathways in a rat model of gastric carcinogenesis induced by methylnitronitrosoguanidine[J]. Environmental Toxicology, 2022, 37(5): 1222-1230.
[2]. Ding L, Ding Y N, Lin Y, et al. Proteins related to early changes in carcinogenesis of hepatic oval cells after treatment with methylnitronitrosoguanidine[J]. Experimental and Toxicologic Pathology, 2014, 66(2-3): 139-146.
[3]. Zhu, F., Xu, Y., Pan, J., Li, M., Chen, F., & Xie, G. (2021). Epigallocatechin gallate protects against MNNG-induced precancerous lesions of gastric carcinoma in rats via PI3K/Akt/mTOR pathway. Evidence-Based Complementary and Alternative Medicine, 2021.
[4]. XU J, ZHANG X, SUN D, et al. Effect of methylnitronitrosoguanidine (MNNG) on the malignant transformation of human gastric mucosa GES-1 cells and its mechanism[J]. Medical Journal of Chinese People's Liberation Army, 2016, 41(11): 887-891.
Cas No. | 70-25-7 | SDF | |
Canonical SMILES | N=C(N[N+]([O-])=O)N(C)N=O | ||
Formula | C2H5N5O3 | M.Wt | 147.09 |
Solubility | DMSO : 125 mg/mL (849.82 mM) | Storage | Store at -20°C,unstable in solution, ready to use. |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 6.7986 mL | 33.9928 mL | 67.9856 mL |
5 mM | 1.3597 mL | 6.7986 mL | 13.5971 mL |
10 mM | 0.6799 mL | 3.3993 mL | 6.7986 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 26 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *